Full-Time

Medical Science Liaison

Rheumatology Northeast

ANI Pharmaceuticals

ANI Pharmaceuticals

501-1,000 employees

Develops, manufactures, markets prescription drugs

Compensation Overview

$165k - $180k/yr

+ Short-term incentive program

Remote in USA

Remote

PharmD, PhD, MD

Category
Medical, Clinical & Veterinary (1)

Get referred to ANI Pharmaceuticals

See people who can refer or advise you

Requirements
  • The qualified candidate will have an advanced degree in a health-sciences related field such as a PharmD, MD, or PhD.
  • 2+ years prior field medical affairs position experience within the pharmaceutical or biotechnology industry.
  • Previous experience in Rheumatology or Immunology (preferred).
  • Willingness to travel 60 % or more of the time.
  • Extensive travel is integral to the performance of this position.
Responsibilities
  • Always comply with company and compliance policies including internal and external guidelines.
  • Ensure the appropriate dissemination of clinical and scientific information regarding marketed and pipeline compounds in a timely, ethical, and customer-focused manner.
  • Implement clinical and educational strategies in collaboration with other ANI colleagues for designated customers that include potential clinical trial site placement and sponsorships.
  • Work to pair our key scientific leaders’ educational and research needs with available ANI resources and will provide the latest emerging data in response to specific healthcare professional inquiries.
  • Present healthcare professionals and decision makers with accurate, unbiased, balanced, and timely answers to unsolicited requests for information about ANI products.
  • Establish scientific and clinical relationships with key opinion leaders and academic centers to expand research and educational opportunities for ANI products.
  • Provide study support where appropriate, from protocol and budget development to submission and completion for company sponsored research as well as investigator-initiated research studies (IIRs).
  • Document and forward reports of adverse events to appropriate ANI personnel.
  • Keep abreast of medical and scientific developments in Rheumatology.
  • Proactively report competitive activities as well as events that can influence the use of ANI products.
  • Develop and deliver very specialized scientific/educational programs including but not limited to formulary presentations for managed care and related organizations.
  • Assist Medical and Scientific Affairs as well as agency personnel in the development of presentations and slide kits.
  • Actively participate in advisory boards, speaker training events, clinical investigator meetings, regional national and international meetings when required.
  • Assist in processing field requests for medical education funding.
  • Actively participate in key medical and scientific conferences by staffing medical information booths, gathering competitive intelligence on competitors, and attending scientific sessions.
  • Represents the organization as a prime field medical contact.
Desired Qualifications
  • Strong clinical knowledge including pharmacotherapy, treatment guidelines, clinical research processes, medical expert engagement strategies, and FDA promotional guidelines, regulations, and ethical guidelines applied to the pharmaceutical industry is preferred.

ANI Pharmaceuticals develops, manufactures, and markets prescription medications, including generic and branded products, that are FDA-approved. Its medicines are produced in regulated facilities and go through standard safety and efficacy testing to meet patient needs. The company sells these products to pharmacies, hospitals, and healthcare providers, using a portfolio that spans generic drugs and specialty branded therapies. What sets ANI apart is its combination of a diversified product lineup with growth through strategic acquisitions to expand its offerings and market reach, rather than relying on a single product area. Its goal is to provide high-quality medicines to patients while continuously expanding its portfolio and market presence through acquisitions and manufacturing capabilities.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Baudette, Minnesota

Founded

1996

Get referred to ANI Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ANI reported Q2 2026 revenue of $266 million, up 25.9%, on August 7.
  • Cortrophin Gel revenue rose 43.5% to $117.1 million, with July new-case records.
  • Management reaffirmed 2026 revenue guidance of $1.08 billion to $1.14 billion and repurchased $100 million.

What critics are saying

  • The July 16, 2026 CG Oncology appeal can still end with zero royalty recovery.
  • The May 2026 Estradiol Gel Class II recall exposed packaging-control weakness at Baudette.
  • Cortrophin concentration leaves ANI vulnerable if gout uptake slows or payer reverification drags through 2026.

What makes ANI Pharmaceuticals unique

  • ANI owns Cortrophin Gel, the only approved ACTH therapy for acute gouty flares.
  • ANI combines rare disease, generics, and U.S.-based manufacturing across 116 pharmaceutical products.
  • ANI’s 2026 sales-force expansion targets podiatrists and primary care, widening specialty distribution fast.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

24%
Yahoo Finance
Aug 16th, 2026
ANI Pharmaceuticals beats Q2 estimates with $266M revenue despite market concerns over Cortrophin guidance

ANI Pharmaceuticals reported second-quarter revenue of $266 million, beating analyst estimates of $259.8 million with 25.9% year-on-year growth. The company's adjusted EPS of $2.21 also surpassed expectations of $2.04. Despite strong performance in rare disease and generics businesses, the market reacted negatively to the results. CEO Nikhil Lalwani highlighted momentum in the third quarter, noting July marked the highest month for new cases initiated. The company reconfirmed its full-year revenue guidance of $1.11 billion at the midpoint and maintained its adjusted EPS guidance of $9.44. Operating margin improved to 15.2%, up from 6.6% in the same quarter last year. Analysts questioned the disconnect between prescription data and revenue, insurance reverification issues, and the rationale behind lowering Cortrophin guidance despite positive demand metrics.

Yahoo Finance
Aug 15th, 2026
ANI Pharmaceuticals posts 26% revenue growth but shares fall 9% on weak guidance

ANI Pharmaceuticals reported Q2 revenues of $266 million, up 25.9% year on year, exceeding analyst expectations by 2.4%. The company beat EPS estimates but slightly missed full-year revenue guidance expectations. Despite posting the fastest revenue growth among the four generic pharmaceuticals stocks tracked, ANI's shares fell 9.1% following the results. The company's portfolio includes 116 pharmaceutical products with a focus on rare disease treatments. Generic pharmaceuticals companies as a group delivered strong Q2 results, with revenues beating consensus estimates by 2.6%. However, the sector has struggled recently, with share prices down 5.6% on average since the latest earnings announcements. The industry faces pricing pressures and thin margins but benefits from consistent demand for affordable medications.

Yahoo Finance
Aug 11th, 2026
ANI Pharmaceuticals Q2 revenue up 26% to $266M, rare disease expansion drives growth

ANI Pharmaceuticals reported Q2 revenue of $266 million, up 25.9% year on year and beating analyst estimates of $259.8 million. The specialty pharmaceutical company's non-GAAP profit of $2.21 per share exceeded consensus by 8.2%. However, the company's full-year revenue guidance of $1.11 billion came in 1% below analyst expectations, prompting a negative market reaction. Management highlighted strong growth in rare disease and generics businesses, driven by expansion of its sales force for Cortrophin Gel. CEO Nikhil Lalwani noted July represented the highest month for new cases initiated. The company is expanding Cortrophin Gel into new specialty areas, particularly gout treatment. Operating margin improved to 15.2% from 6.6% in the prior year period.

Yahoo Finance
Aug 7th, 2026
ANI Pharmaceuticals Q2 revenue jumps 26% to $266M on Cortrophin Gel growth, cuts 2026 guidance

ANI Pharmaceuticals reported record second-quarter results, with revenue rising 26% year-over-year to $266 million and adjusted EBITDA increasing 32% to $71.6 million. Adjusted earnings per share reached $2.21. Cortrophin Gel, the company's rare-disease treatment, drove growth with revenue climbing 43% to $117.1 million. ANI expanded its rare-disease sales force by 50% to approximately 180 representatives, including a new gout-focused team. The company maintained its full-year revenue guidance of $1.08 billion to $1.14 billion and adjusted EBITDA guidance of $285 million to $300 million. However, it lowered 2026 Cortrophin guidance to $520 million to $540 million based on first-half results. Cash reached $360.2 million, supported by $115 million in first-half operating cash flow.

Yahoo Finance
Aug 7th, 2026
ANI Pharmaceuticals Q2 sales beat estimates at $266M but stock drops on weak guidance

ANI Pharmaceuticals reported Q2 2026 revenue of $266 million, beating analyst estimates of $259.8 million and marking 25.9% year-on-year growth. The specialty pharmaceutical company's adjusted earnings per share of $2.21 also exceeded expectations by 8.2%. Despite the strong quarterly performance, ANI's stock dropped following the release. The company's full-year revenue guidance of $1.11 billion came in 1% below analyst estimates. ANI has demonstrated robust long-term growth, with revenue expanding at a 35.6% compound annual growth rate over the past five years. The company's portfolio includes 116 pharmaceutical products and a growing rare disease platform. President and CEO Nikhil Lalwani highlighted the quarter's "outstanding financial results" alongside the implementation of the company's largest rare disease sales force expansion.